The Swiss biotech company Memo Therapeutics AG closes a series A financing round of 2.3 million Swiss Francs to develop and validate its MemoMABTM antibody discovery platform
Memo Therapeutics AG today announced the successful completion of its series A financing round of 2.3 million Swiss Francs which has been raised from Swiss investors (including EVA Basel, Redalpine Venture Partners and Zürcher Kantonalbank). The funds will be used to develop and validate its MemoMABTM antibody discovery platform. MemoMABTM will be used for discovery of novel human-derived antibodies and of antibodies against difficult targets from animals.
The technological core of Memo Therapeutics is MemoMABTM – a technology enabling cost and time-efficient molecular cloning and recombinant expression of the complete antibody repertoires of human and animal species. MemoMABTM utilizes nanoliter reactor technology to increase throughput and performance of biological assays.
About Memo Therapeutics
Memo Therapeutics AG is a Basel/Zurich based Swiss biotech start-up company. It is a spin-off from the ETH Zurich, Switzerland.